TempusAI Growth Accelerates on Genomics and Data Partnerships

Tempus AI, a healthcare technology company applying AI in healthcare, reported strong Q2 growth fueled by rising genomics volumes across its oncology testing portfolio, robust hereditary testing performance, and major data licensing deals with biopharmaceutical firm AstraZeneca and AI-enabled biotechnology company Pathos AI, Inc.  

Genomics as a Growth Driver

Genomics—the study of an organism’s full set of genes and how they interact with each other and the environment—has applications in a range of fields, including personalized medicine, drug discovery, agriculture, and forensic science, according to the World Health Organization (WHO).

Tempus has used genomics to grow its business by combining large-scale genomic testing with its large-scale AI platform. Its February acquisition of Ambry Genetics significantly expanded both capabilities and revenue, while new offerings such as the xM liquid biopsy assay are improving treatment monitoring and driving revenue growth. 

The company’s genetic testing provides personalized DNA reports designed to help physicians tailor treatments for cancer, mental health, hereditary risks, and other conditions. The company’s platform analyzes a patient's genomic profile and integrates it with other clinical data to help inform decisions and improve treatment outcomes.

Partnerships and Acquisitions

Tempus leaders announced the AstraZeneca and Pathos collaborations in April, saying the companies will build a multimodal foundation model in oncology to gather biological and clinical insights, discover novel drug targets, and develop therapeutics for the broader oncology community. Tempus’ de-identified oncology data will power the model, and all three companies will use the model to enhance their research efforts. The agreements include $200 million in data licensing and development fees for Tempus.

The agreement with AstraZeneca expands their partnership announced in 2021 and will apply Tempus’ AI-enabled platform and multimodal datasets advance therapeutic oncology programs on a global scale.

Tempus CEO Eric P. Lefkofsky said the company is exploring additional partnerships, noting that other companies are considering building similar models. He emphasized the transformative potential of these tools for both R&D pipelines and existing drugs.

Management is already partners with several other organizations, including:

• Illumina, to broaden genomic testing beyond oncology and strengthen AI-driven insights.
• Global pharmaceutical company Boehringer Ingelheim, to advance its cancer pipeline, building on prior joint work that leveraged data and AI to drive therapeutic research and development.
• Stemline Therapeutics, to advance oncology treatments to use Tempus’ AI-enabled Next platform to help clinicians identify when an ESR1 test might be appropriate.
• RNA-biomarker company Genialis, in a multiyear agreement, allowing Genialis to use Tempus’ multimodal dataset to develop new RNA-based algorithms across cancer types.
• The Abrams Research Center on Neurogenomics at Northwestern University Feinberg School of Medicine, to use Tempus’ AI-powered Lens platform for analyzing and restructuring genomic data in Alzheimer’s research.
• Institute for Follicular Lymphoma Innovation, to create a multimodal, de-identified FL data library in Lens to provide AI-driven insights to accelerate follicular lymphoma treatment development and improve patient outcomes.

Financial Performance and Outlook

During its Q2 earnings call, Lefkofsky raised the company’s 2025 revenue forecast to $1.26 billion, citing both disciplined cost management and growth opportunities in diagnostics and AI-driven data products.

For Q2, revenue rose 89.6% to $314.6 million. Genomics revenue climbed a massive 115% to $241.8 million, oncology volumes grew from 20% last quarter to 26% this quarter, and hereditary testing was up 32%.

Lefkofsky noted, however, that a lack of reimbursement mechanisms in the U.S. healthcare system for AI or algorithms limits the financial these products until reimbursement pathways are established.